%D9%85%D8%AA%D9%84%D8%A7%D8%B2%D9%85%D8%A9_%D9%81%D9%8A%D8%B3%D9%83%D9%88%D8%AA_%D8%A2%D9%84%D8%AF%D8%B1%D9%8A%D9%83%E0%A6%89%E0%A6%87%E0%A6%B8%E0%A7%8D%E0%A6%95%E0%A6%9F_%E0%A6%85%E0%A6%B2%E0%A7%8D%E0%A6%A1%E0%A7%8D%E0%A6%B0%E0%A6%BF%E0%A6%9A_%E0%A6%B8%E0%A6%BF%E0%A6%A8%E0%A6%A1%E0%A7%8D%E0%A6%B0%E0%A7%8B%E0%A6%AECategory:Wiskott-aldrich_syndromeWiskott-Aldrich-SyndromWiskott%E2%80%93Aldrich_syndromeS%C3%ADndrome_de_Wiskott-Aldrich%D8%B3%D9%86%D8%AF%D8%B1%D9%85_%D9%88%DB%8C%D8%B3%DA%A9%D9%88%D8%AA-%D8%A2%D9%84%D8%AF%D8%B1%DB%8C%DA%86Syndrome_de_Wiskott-Aldrich%D7%AA%D7%A1%D7%9E%D7%95%D7%A0%D7%AA_%D7%95%D7%99%D7%A1%D7%A7%D7%95%D7%98-%D7%90%D7%95%D7%9C%D7%93%D7%A8%D7%99%D7%A5%27Wiskott%E2%80%93Aldrich-szindr%C3%B3maSindrom_Wiskott%E2%80%93AldrichSindrome_di_Wiskott-Aldrich%EB%B9%84%EC%8A%A4%EC%BD%94%ED%8A%B8-%EC%98%AC%EB%93%9C%EB%A6%AC%EC%B9%98_%EC%A6%9D%ED%9B%84%EA%B5%B0Syndroom_van_Wiskott-AldrichZesp%C3%B3%C5%82_Wiskotta-AldrichaS%C3%ADndrome_de_Wiskott-Aldrich%D0%A1%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC_%D0%92%D0%B8%D1%81%D0%BA%D0%BE%D1%82%D1%82%D0%B0_%E2%80%94_%D0%9E%D0%BB%D0%B4%D1%80%D0%B8%D1%87%D0%B0Wiskott-Aldrich_syndromeWiskott-Aldrichs_syndrom%E0%B8%81%E0%B8%A5%E0%B8%B8%E0%B9%88%E0%B8%A1%E0%B8%AD%E0%B8%B2%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B8%A7%E0%B8%B4%E0%B8%AA%E0%B8%81%E0%B9%87%E0%B8%AD%E0%B8%95%E0%B8%95%E0%B9%8C-%E0%B8%AD%E0%B8%B1%E0%B8%A5%E0%B8%94%E0%B8%A3%E0%B8%B4%E0%B8%8AQ953638
about
sameAs
Gene Therapy for WASConditioning Regimen for Allogeneic Hematopoietic Stem-Cell TransplantationGene Therapy for Wiskott-Aldrich SyndromeGene Therapy for Wiskott-Aldrich Syndrome (WAS)Alefacept and Allogeneic Hematopoietic Stem Cell TransplantationTargeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)Molecular and Clinical Studies of Primary Immunodeficiency DiseasesA Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary ImmunodeficiencyAllogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesA Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich SyndromePilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich SyndromePatients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990Participation in a Research Registry for Immune DisordersBMT Abatacept for Non-Malignant DiseasesFludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesThrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) PatientsStudy of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS)Interleukin-2 Treatment for Wiskott-Aldrich SyndromeUnrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood CellsFludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerRelated Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood CellsGene Therapy for WAS Follow-upSequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency DiseasesEfficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsHaploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich SyndromePost-transplant Cyclophosphamide in Wiskott-Aldrich SyndromeAllogeneic Bone Marrow Transplantation in Patients With Primary ImmunodeficienciesStudy of Genetic and Molecular Defects in Primary Immunodeficiency DisordersA Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS PatientsImmune Disorder HSCT ProtocolRomiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
P1050
P2293
Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting proteinStructure of Cdc42 in complex with the GTPase-binding domain of the 'Wiskott-Aldrich syndrome' proteinAutoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome proteinScar/WAVE-1, a Wiskott-Aldrich syndrome protein, assembles an actin-associated multi-kinase scaffoldWiskott-Aldrich syndrome protein controls antigen-presenting cell-driven CD4+ T-cell motility by regulating adhesion to intercellular adhesion molecule-1Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASPHematopoietic lineage cell-specific protein 1 functions in concert with the Wiskott-Aldrich syndrome protein to promote podosome array organization and chemotaxis in dendritic cellsCD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1Identification of novel SH3 domain ligands for the Src family kinase Hck. Wiskott-Aldrich syndrome protein (WASP), WASP-interacting protein (WIP), and ELMO1A hydrophobic pocket in the active site of glycolytic aldolase mediates interactions with Wiskott-Aldrich syndrome proteinEnhancement of T-cell activation by the CD43 molecule whose expression is defective in Wiskott-Aldrich syndromeIdentification of splicing variants of Rapostlin, a novel RND2 effector that interacts with neural Wiskott-Aldrich syndrome protein and induces neurite branchingPhosphorylation of tyrosine 291 enhances the ability of WASp to stimulate actin polymerization and filopodium formation. Wiskott-Aldrich Syndrome proteinWiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerizationWiskott-Aldrich syndrome protein is involved in alphaIIb beta3-mediated cell adhesionThe Cdc42/Rac interactive binding region motif of the Wiskott Aldrich syndrome protein (WASP) is necessary but not sufficient for tight binding to Cdc42 and structure formationWASH and WAVE actin regulators of the Wiskott-Aldrich syndrome protein (WASP) family are controlled by analogous structurally related complexesWIP, a protein associated with wiskott-aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cellsEvidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathwaysSorting nexin 33 induces mammalian cell micronucleated phenotype and actin polymerization by interacting with Wiskott-Aldrich syndrome proteinIsolation of a novel gene mutated in Wiskott-Aldrich syndromeWiskott-Aldrich syndrome protein (WASp) and N-WASp are involved in the regulation of NK-cell migration upon NKG2D activationNeural Wiskott-Aldrich syndrome protein is implicated in the actin-based motility of Shigella flexneriWiskott-Aldrich syndrome protein is associated with the adapter protein Grb2 and the epidermal growth factor receptor in living cellsDirect interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndromeSyndapin I, a synaptic dynamin-binding protein that associates with the neural Wiskott-Aldrich syndrome proteinWiskott-Aldrich syndrome protein physically associates with Nck through Src homology 3 domainsWiskott-Aldrich syndrome protein regulates podosomes in primary human macrophagesA novel neural Wiskott-Aldrich syndrome protein (N-WASP) binding protein, WISH, induces Arp2/3 complex activation independent of Cdc42The intersectin 2 adaptor links Wiskott Aldrich Syndrome protein (WASp)-mediated actin polymerization to T cell antigen receptor endocytosisInteraction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cellsThe Wiskott-Aldrich syndromeModelling of human Wiskott-Aldrich syndrome protein mutants in zebrafish larvae using in vivo live imagingUnraveling the repertoire in wiskott-Aldrich syndromeWiskott-Aldrich syndrome; an x-linked primary immunodeficiency disease with unique and characteristic featuresc-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by gliomasThe chemotactic defect in wiskott-Aldrich syndrome macrophages is due to the reduced persistence of directional protrusionsImpaired integrin-dependent function in Wiskott-Aldrich syndrome protein-deficient murine and human neutrophils.WASp family verprolin-homologous protein-2 (WAVE2) and Wiskott-Aldrich syndrome protein (WASp) engage in distinct downstream signaling interactions at the T cell antigen receptor site
P921
Q61955972-D7C25386-2714-4280-8076-CF28586EFF45Q62819286-8F8B107B-B0F7-41BE-A4F4-6C4304EDF419Q63317001-E81D5A4C-FECD-4EEA-9870-56C99476971EQ63335831-4B134AEE-4608-4CBB-BFDA-3CA9E555DBB2Q63336803-6A5FEA16-5B00-41E3-B85B-E7166D6C8E0AQ63402423-D5607943-EBB1-4C31-9F5C-7CE02839FC86Q63577221-A4D7DF3A-0E13-4ED7-B01B-04D3FC31E20EQ63814218-1D9292BB-EBDE-45D3-B202-F1E1DAF57FEBQ63838240-C343C034-678E-404E-87C4-9D2A36C8FDD2Q64139920-5E72B533-2FEA-45DE-BC95-B6F3E2B3CE1FQ64187108-0869D71F-C06C-4FAB-98D2-303FAC43C317Q64223131-6817E516-AE0E-490E-A370-4034DF9017CEQ64353512-C3C2A192-F20D-4BBA-99F2-4425EAB8BA68Q64622785-7D676FB2-5FC8-4559-8A1B-80B6136B3FF5Q64672690-88C0D825-BCD5-4795-BD79-748180B1F56DQ64675474-05AA3492-5A3E-49E9-B4ED-530E18B8C0FEQ64678735-63E6957D-9EA9-43C9-AA6F-88576C5ACE56Q64715170-4F96817B-C672-462C-9726-F05DB0FBA1A0Q64717899-101C8AB6-5D91-49F3-A9F0-BE4952A99D39Q64790128-A1FE5522-04C8-4ED7-8921-DFDF62218305Q65337365-E35ED191-636B-4585-A2F0-BB819F6251C6Q65350576-A3B77FC9-AA49-41FF-B30B-5A00C6B8DACFQ65364424-3FDFCC5F-AA86-4453-95EA-9BAAF93CFAFDQ65538851-2F82F9F6-C7ED-4B25-8695-462D67D1B2E1Q65543911-CA9CC33C-291B-4DB5-99EC-94AE27603CA9Q66027483-CC3EA089-42B2-446E-8A4F-23A3B3750E90Q66042674-11B3943A-2D82-4C0B-BA4F-0C77C05B91E8Q66060096-7448F7DD-2649-4B01-B9EC-EB02953DABFDQ66062050-2080BD80-2903-44E9-A871-75821AA416ACQ66075167-2C1A99B3-5216-47DD-A72C-4E070A702680Q66344455-23DCF0E3-6F55-4576-8055-2F84AD5A22C4Q92274165-6B0DF5C5-9714-4487-BF5A-2D28765B4C82Q93214708-69ED2A56-D30B-4B97-BE43-CD2C2789CC48
P1050
description
X-chromosomal rezessiv vererbte Krankheit
@de
rare disease
@en
врождённый иммунодефицит, сопровождающийся склонностью к экземе и фатальным кровотечениям
@ru
name
Sindrom Wiskott–Aldrich
@id
Syndroom van Wiskott-Aldrich
@nl
Síndrome de Wiskott-Aldrich
@es
Síndrome de Wiskott-Aldrich
@pt
Wiskott-Aldrich syndrome
@en
Wiskott-Aldrich-Syndrom
@de
Wiskott-Aldrich-en sindrome
@eu
Wiskott-Aldrichs syndrom
@sv
Wiskott–Aldrich-szindróma
@hu
Wiskott–Aldrich綜合徵
@zh
type
label
Sindrom Wiskott–Aldrich
@id
Syndroom van Wiskott-Aldrich
@nl
Síndrome de Wiskott-Aldrich
@es
Síndrome de Wiskott-Aldrich
@pt
Wiskott-Aldrich syndrome
@en
Wiskott-Aldrich-Syndrom
@de
Wiskott-Aldrich-en sindrome
@eu
Wiskott-Aldrichs syndrom
@sv
Wiskott–Aldrich-szindróma
@hu
Wiskott–Aldrich綜合徵
@zh
altLabel
Aldrich Syndrome
@en
Eczema thrombocytopenia immunodeficiency syndrome
@en
Eczema-Thrombocytopenia-Immunodeficiency Syndrome
@en
IMD 2
@en
Immunodeficiency 2
@en
Sindrome de Wiskott-Aldrich
@es
WAS
@en
WISKOTT-ALDRICH SYNDROME
@en
WISKOTT-ALDRICH SYNDROME; WAS
@en
Wiskott Aldrich syndrome
@en
prefLabel
Sindrom Wiskott–Aldrich
@id
Syndroom van Wiskott-Aldrich
@nl
Síndrome de Wiskott-Aldrich
@es
Síndrome de Wiskott-Aldrich
@pt
Wiskott-Aldrich syndrome
@en
Wiskott-Aldrich-Syndrom
@de
Wiskott-Aldrich-en sindrome
@eu
Wiskott-Aldrichs syndrom
@sv
Wiskott–Aldrich-szindróma
@hu
Wiskott–Aldrich綜合徵
@zh
P279
P2888
P492
P672
P673
P486
P5806
P6366
P646
P672
P1296
P1692
P1748
P1995
P279
P2892
P3827
wiskott-aldrich-syndrome
P4229
P486
P492
P5270
MONDO:0010518